EAACI Congress 2025
BackTPS09 - Allergen immunotherapy 02
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D1.155
Alterations in B cell memory induced by house dust mite allergen immunotherapy
D1.158
Assessment of the Efficacy of Specific Immunotherapy After a Long Break in Asthmatic Patients
D1.156
Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients
D1.163
IgE High-Affinity Receptor Expression as a Predictive Biomarker for Oral Immunotherapy Outcomes in Severe Egg and Milk Allergies
D1.152
Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units
D1.149
Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma
D1.153
Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
D1.154
Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix
D1.162
Selecting the right immunotherapy for Vespa velutina nigrithorax anaphylaxis: does one treatment fits all?
D1.150
Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)
D1.159
The successful resolve of nasal polyps in patient with dupilumab treatment
D1.157
Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis
